Ustekinumab biosimilar for treating moderate to severe plaque psoriasis

Ustekinumab biosimilar is in clinical development for adults with moderate to severe plaque psoriasis. Plaque psoriasis, which is the most common type of psoriasis, is a long-lasting inflammatory disease causing red, flaky and itchy patches of skin commonly appearing on the elbows, knees, scalp and lower back. Plaque psoriasis is an autoimmune disease, meaning that part of the body's own immune system becomes overactive and attacks normal tissues in the body, in this case, the skin. Treatment for moderate to severe psoriasis usually involves the administration of biologic systemic (oral or injected) therapies which alter the immune system in a way that disrupts the disease cycle and improves symptoms and signs of disease, however these types of drugs are expensive.